Efficacy, Safety, and Tolerability of Pertuzumab, Trastuzumab, and Docetaxel for Patients With Early or Locally Advanced ERBB2-Positive Breast Cancer in Asia
2019 · JAMA Oncology · 184 citations
https://doi.org/10.1001/jamaoncol.2019.3692
J
Junjie Li
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
28
Papers
573
Citations
12
h-index
12
i10-index
Junjie Li is an academic researcher from Fudan University Shanghai Cancer Center. The author has contributed to research in topics: HER2/EGFR in Cancer Research & Breast Cancer Treatment Studies & Monoclonal and Polyclonal Antibodies Research. The author has an h-index of 12, co-authored 24 publications.
ORCID: 0000-0002-9672-7399Papers by this author
worksDiscovery of a Potential HER2 Inhibitor from Natural Products for the Treatment of HER2-Positive Breast Cancer
2016 · International Journal of Molecular Sciences · 36 citations
https://doi.org/10.3390/ijms17071055
Spatial determinants of antibody-drug conjugate SHR-A1811 efficacy in neoadjuvant treatment for HER2-positive breast cancer
2025 · Cancer Cell · 27 citations
https://doi.org/10.1016/j.ccell.2025.03.017
Use of trastuzumab as an adjuvant/neoadjuvant therapy in patients with HER2-positive breast cancer in China
2018 · Medicine · 17 citations
https://doi.org/10.1097/md.0000000000010350
Enhancing understanding of flame morphology and heat flux of sidewall fire: The effect of crosswind perpendicular to the sidewall
2025 · Applied Thermal Engineering · 0 citations
https://doi.org/10.1016/j.applthermaleng.2025.128248
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat